KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
March 30, 2022 16:05 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing...
Global Psychedelic Drugs Market Research Report 2022-2025: Rising Number of Potential Candidates for BTD & Surging Popularity of Micro-dosing in Psychedelics
March 28, 2022 07:28 ET
|
Research and Markets
Dublin, March 28, 2022 (GLOBE NEWSWIRE) -- The "Global Psychedelic Drugs Market: Analysis By Indication (ADHD, MDD, Bipolar, Migraine, Anxiety, Parkinson's Disease, OUD, Alzheimer's Disease, AUD,...
KemPharm to Report Fourth Quarter and Full-Year 2021 Results
March 10, 2022 07:30 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, March 30, 2022, 5:00 p.m. ET CELEBRATION, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- KemPharm,...
Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD
February 15, 2022 09:00 ET
|
Neurocentria, Inc
WALNUT CREEK, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, Attention Deficit...
Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction
January 25, 2022 22:30 ET
|
NeuroSigma, Inc.
Ignis obtains rights to develop and commercialize NeuroSigma’s FDA-approved Monarch eTNS System in ChinaInitial launch of Generation 1.0 device followed by Generation 1.5 device, to deploy in mainland...
How UFS research assists teachers in identifying children who need developmental help
January 19, 2022 05:21 ET
|
University of the Free state
Bloemfontein, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Research done by the University of the Free State (UFS) has shown that Grade 1 learners not only experience visual problems, but also developmental...
NeuroSigma Announces Promotion of Dr. Colin Kealey to President
January 11, 2022 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced the promotion of Dr. Colin Kealey to President. NeuroSigma is the developer...
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
December 23, 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Topline results from pivotal SEAL study expected in Q1 2022 - If approved, ADAIR will target the growing Adderall® segment of the ~$9 billion U.S. ADHD market PHILADELPHIA, PA, Dec. ...
NeuroSigma Announces a $5 Million Equity Investment by KT Corporation
December 08, 2021 05:00 ET
|
NeuroSigma, Inc.
Transaction follows the June 2021 announcement of a strategic digital health partnership between NeuroSigma and KTSignificant investment in NeuroSigma’s digital health and neuro-electronics platform ...
OWP Pharmaceuticals Announces IND Authorization for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder
November 17, 2021 08:00 ET
|
OWP Pharmaceuticals, Inc.
NAPERVILLE, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...